Lumosa Therapeutics Co., Ltd. board approved the exclusive licensing agreement of LT1001, a long-acting analgesic injection, with Pakistan's AJM Pharma Pvt. Ltd. (AJM). Lumosa is responsible for supplying LT1001 to AJM while AJM is responsible for the registration, marketing, and sales of LT1001 in Pakistan.

Contract period: From the execution of the agreement until 10 years after the first marketing of the product. Both parties may negotiate contract extensions. Taiwan Ministry of Science and Technology and National Defense Medical Center licensed the exclusive development and commercialization rights and relevant technologies of LT1001 to Lumosa.

In turn, Lumosa shall pay 20% of considerations from the sub-license fee to the licensor, as well as 1.875%~3.75% royalty from the sales of LT1001 long-acting analgesic injection.